Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Tokyo Electric Power Shares Surge as Kashiwazaki-Kariwa Nuclear Reactor Restart Nears 
Samsung Electronics Poised for Massive Q4 Profit Surge on Soaring Memory Chip Prices 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Mercedes-Benz to Launch Advanced Urban Self-Driving System in the U.S., Challenging Tesla FSD 
Saks Global Enterprises Seeks $1 Billion Loan Amid Possible Chapter 11 Bankruptcy Filing 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
CAMBRIDGE, Mass., Oct. 23, 2017 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that it will report preclinical data on its second product candidate, XMT-1536, in a poster to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic, held October 26-30 in Philadelphia. Presentation details are as follows:
| Title: | Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models | ||
| Session: | Poster Session B, Therapeutic Agents: Biological | ||
| Presenter: | Rebecca Mosher, M.D., Executive Director, Translational Medicine | ||
| Date and Time: | Sunday, October 29, 2017, 12:30 p.m. - 4:00 p.m. ET | ||
| Poster/Abstract: | 119/B119 |
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
(212) 362-1200
